Sarasota-based Omeza closed on its most recent funding round on March 28, exceeding its $5MM goal by $0.75MM and attracting its board members in the process. A medtech and consumer healthcare company, Omeza invited a select group of individuals to invest in its breakthrough technology, which is initially aimed at healing and preventing chronic leg and foot ulcers. Currently launching the second of its core OmezaTM omega oil products, the company will focus on evidence generation this quarter, as well as building out its marketing, sales and logistics capacity.

With the close of this round came the appointment of a Board of Managers. Omeza’s Board Chairman is Joel Morganroth, M.D., P.C., former CEO of (ERT) eResearch Technology Inc. Additional Board members are Ronald G. Gelbman, Executive Committee Member and Chairman of Pharmaceuticals and Diagnostics at Johnson & Johnson; Robert A. Essner, former Chairman and Chief Executive Officer of Wyeth; A.G. Lafley, former Chairman and CEO of Procter & Gamble; and Thomas Gardner, Omeza CEO and Founder.

Omeza